Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Sodium fluoride study

This article was originally published in The Tan Sheet

Executive Summary

Sodium fluoride study: Final report of a trial on the treatment of osteoporosis with 25 mg sodium fluoride twice daily concludes that "slow-release sodium fluoride and calcium citrate administered for four years inhibits new vertebral fractures (but not recurrent fractures), augments spinal and femoral neck bone mass, and is safe to use." The randomized controlled study by researchers from the University of Texas Southwestern Medical Center and the Scott and White Clinic led by Charles Pak, MD, was published in the Sept. 15 Annals of Internal Medicine. Sodium fluoride is the subject of an investigational new drug application sponsored by the University of Texas Southwestern Medical Center, which holds the rights to the drug. Mission Pharmacal supplied the Slow Fluoride for the trial...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel